Financial News
Latest News about VRTX
Recent news which mentions VRTX
Better Growth Stock: Archer Aviation or Prime Medicine?
December 19, 2023
From Motley Fool
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
December 18, 2023
From Motley Fool
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
December 16, 2023
From Motley Fool
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
December 16, 2023
From Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
From InvestorPlace
After This Landmark Win, Is CRISPR Therapeutics a Buy?
December 15, 2023
From Motley Fool
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030
December 14, 2023
From InvestorPlace
From InvestorPlace
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 13, 2023
From Benzinga
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
December 13, 2023
From Benzinga
Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial
December 13, 2023
Tickers
VRTX
From Benzinga
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
December 13, 2023
From InvestorPlace
From MarketWatch
1 Biotech Stock That Could Be the Next Amgen
December 13, 2023
From Motley Fool
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
December 13, 2023
From Motley Fool
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
From InvestorPlace
Why CRISPR Stock Keeps Falling
December 11, 2023
From Motley Fool
From Motley Fool
3 Unstoppable Stocks to Buy Right Now
December 10, 2023
From Motley Fool
From Motley Fool
Forget the "Magnificent Seven": Buy This Stock Instead
December 09, 2023
Tickers
VRTX
From Motley Fool
From Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 08, 2023
From Benzinga
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
December 08, 2023
From MarketWatch
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
December 08, 2023
From Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
December 07, 2023
From InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
December 07, 2023
From Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
December 07, 2023
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.